JOIN US AT BIOPHARMACHEM IMPACT 2026

To many, AI adoption in life sciences looks like a technology problem. It mostly isn't. The capability is largely there.

To others, it looks like a regulatory problem. Yet regulators have signalled openness in principle.

So some are calling it a capability problem. But the same organisations that have built validated digital infrastructure for decades aren't suddenly incapable.

So - what is it?

Well, in an unregulated industry, a business with conviction and capital just moves. In a regulated one, the cost of moving first and being wrong brings asymmetric downside.

The penalty for an early misstep on a GxP-validated AI system is materially worse than the penalty for a six-month delay. Which is why rational individual behaviour can produce collective stasis.

The industry often waits for proof from peers and clarity from regulators. Regulators wait for industry to show what 'good' looks like in practice. And suppliers (well, not Brightbeam, we have better methods) wait for buyers to define requirements specific enough to validate against.

None of these waits is irrational. Each actor is doing the sensible thing given what they know about the others. It's a 'who moves first' problem.

Which is why the conversations at BioPharmaChem Ireland's Impact event

next week could be rather significant. What's being done in practice will become more visible. And the conversation itself is likely to move the frame.

Brian Hanly, our CEO, is chairing 'Digitalisation & AI in a GxP Environment'. The panel brings together senior leaders from Pfizer, MSD, Amgen, SkyCell and PMTC.

Do come and join us. Our clients are already past the 'who moves first' question. And we have a sneaking suspicion you'll quickly get a feel for how 'last year' that frame has become.

No asymmetric downside here. 👇